Characterization of human S-adenosyl-homocysteine hydrolase in vitro and identification of its potential inhibitors

Weiwei Hao*, Yanhua Li*, Qiuli Shan*, Tian Han, Wencheng Li, Sheng He, Kongkai Zhu, Yumei Li, Xiaojun Tan and Jinsong Gu

School of Biological Science and Technology, University of Jinan, Jinan, China

ABSTRACT

Human S-adenosyl-homocysteine hydrolase (SAHH, E.C.3.3.1.1) has been considered to be an attractive target for the design of medicines to treat human disease, because of its important role in regulating biological methylation reactions to catalyse the reversible hydrolysis of S-adenosylhomocysteine (SAH) to adenosine (Ado) and L-homocysteine (Hcy). In this study, SAHH protein was successfully cloned and purified with optimized, Pichia pastoris (P. pastoris) expression system. The biological activity results revealed that, among the tested compounds screened by ChemMapper and SciFinder Scholar, 4-(3-hydroxyprop-1-en-1-yl)-2-methoxyphenol (coniferyl alcohol, CAS: 458-35-5, ZINC: 12359045) exhibited the highest inhibition against rSAHH (IC₅₀ = 34 nM). Molecular docking studies showed that coniferyl alcohol was well docked into the active cavity of SAHH. And several H-bonds formed between them, which stabilized coniferyl alcohol in the active site of rSAHH with a proper conformation.

Introduction

Serum homocysteine (Hcy) levels have been associated with age-related degenerative diseases, such as Alzheimer’s disease (AD), cardiovascular diseases, and stroke, etc.1-3 Elevated levels of Hcy can lead to elevated β-amyloid4, and increased levels of Hcy have been linked to morphological changes in hippocampal volume, to brain atrophy and to cognitive decline5. In the case of AD, high levels of Hcy appear approximately 5–8 years prior to the onset of Alzheimer’s dementia. Therefore, control of Hcy levels might present a novel strategy for AD prevention.

In eukaryotes, Hcy mainly derives from hydrolysis of S-adenosyl-homocysteine (SAH) to adenosine catalysed by S-adenosyl-homocysteine hydrolase (SAHH, E.C.3.3.1.1), as well as from diet6,7. Consequently, SAHH represents a potential drug target for the treatment of AD. Our initial objectives for this program were to characterize human S-adenosyl-homocysteine hydrolase in vitro, and to identify its efficient inhibitors. Furthermore, the inhibition of SAHH can lead to intracellular SAH accumulation, which triggers the negative feedback inhibition to suppress the S-adenosyl-L-methionine (SAM)-dependent transmethylation8 (Figure 1). Because of the prominent role of SAM-dependent transmethylation in capped methylated structure production at the 5' terminus of viral mRNA, SAHH inhibitors could also be developed to be broad-spectrum antiviral agents9-11.

Materials and methods

Chemicals

Sepharose-4B, protein assay reagents, and chemicals for electrophoresis were purchased from Sigma–Aldrich (St. Louis, MO). Molecular compounds used for enzyme inhibition were purchased from J&K SCIENTIFIC Ltd. All other chemicals were of analytical grade and obtained from Sinopham Chemical Reagent Co., Ltd. (Jinan, China).

Strains and culture medium

Pichia pastoris (P. pastoris) GS115 and vector pPIC9K were gifts from Dr Weifeng Liu’s laboratory of Shandong University. Plasmid pPIC9K was used to construct multi-copy expression vectors in vitro. All culture media, including minimal dextrose (MD), buffered minimal glycerol (BMG) and buffered minimal methanol (BMMY) were prepared according to the P. pastoris expression manual (Invitrogen).

Construction of recombinant pPIC9K-sahh

DNA manipulations were performed using standard methods12. Pichia pastoris was manipulated as described in the manual of the EasySelect™ Pichia Expression Kit (Invitrogen, Carlsbad, CA).

The optimized gene forward primer (5’AOX: GACTGGTTCCAATTGACAAGC) and reverse primer (3’AOX: GGCAAAATGGCATCAGACATCCT) were designed according to the predicted sequence of sahh (GenBank accession number BT006697.1). The optimized coding sequence of SAHH for P. pastoris was synthesized by GENEWIZ Inc. (Suzhou, China) and inserted into pPIC9K vector. The recombinant plasmid pPIC9K-sahh was verified by digesting with EcoR I and Not I, and then the target fragment was electrolaminated into P. pastoris obtained by linearizing the plasmid with Bgl II. To facilitate the upcoming purification of the recombinant sahh, a 6 × His tag-encoding sequence
was in-frame fused to the 3'-end of the sahh coding sequence. Other than this, the nucleotide sequence for the restriction site EcoRI were sequentially incorporated at the 5'-end of the synthesized oligonucleotides and the NotI restriction site sequence were added to the 3'-end of the sahh coding sequence, respectively. The generation of the P. pastoris expression vector pPIC9K-sahh was verified by both restriction endonuclease analysis and direct nucleotide sequencing.

*Pichia pastoris* was transformed by electroporation. In brief, 20 μL of BglII-linearized pPIC9K-sahh was mixed with 80 μL of competent *P. pastoris* cells. The cell mixture was kept on ice for 5 min, and then pulsed at 1500 V, 25 mF of capacitance and 200 Ω of resistance for 5 ms using a Gene Pulser Xcell apparatus (Bio-Rad Laboratories Inc., Philadelphia, PA). One milliliter of ice-cold sorbitol (1 M) was immediately added to the cuvette following electroporation. At last, each 50 μL of aliquots was spread on separate yeast MD plates containing 0.25 mg/mL of G418. Plates were incubated for 3–4 days at 30°C.

The *r*sahh-positive *P. pastoris* transformants, which include *sahh* gene fragment and can grow on the medium containing G418, were screened by colony-PCR assay. Single clone of G418-resistant *P. pastoris* transformants was selected and cultured on new yeast YPD. The culture supernatant was employed for PCR amplification using the pPIC9K vector-targeting primer pair. The PCR amplification was performed for 35 cycles at a condition of 94°C for 60 s, 55°C for 60 s and 72°C for 90 s. Mock GS115 containing an empty pPIC9K and the recombinant plasmid pPIC9K-sahh were used as a negative and positive control, respectively. Then, the positive transformants were further cultured on new yeast YPDS plates containing 1.5 mg/mL of G418 to select high-copy expression strains.

**SAHH activity determination**

The activity of SAHH was expressed in units (U), which were defined as 1 μmol of SAH catalyzed by the enzyme per minute. Specific enzymatic activities (a spec) were calculated through the division of the enzymatic activities by the total protein amount used per assay and are expressed in U/mg. SAHH enzyme reacted with the SAH at different temperature and different pH, in order to identify its optimal reaction conditions. All of the values shown correspond to the mean values of at least three independent experiments, each of which was conducted in duplicate and all of the calculations were performed using Origin version 8.5 software and GraphPad Prism 5.

The enzyme kinetic parameters (Km and Kcat) were calculated by least-squares fitting of the activity data at various substrate concentrations.
concentrations to the Michaelis–Menten equation with Origin version 8.5 software (Microcal Software, Northampton, MA).

**Inhibitors’ screening and molecular docking**

Compounds structures were obtained through the ChemMapper platform (http://lilab.ecust.edu.cn/chemmapper/). Stock solution of compounds (1 mM) for enzyme inhibition was prepared in DMSO. Both enzymes and substrates are diluted in Tris-HCl (pH = 6.5) to specified concentration when used for IC50 determination.

Molecular docking was performed with autodock 4.2 program. Here, the X-ray crystallographic structure of SAHH (PDB code: 1A7A) was selected for docking analysis. The beta chain of protein and heteroatoms were removed from the original PDB file. The ligand coniferyl alcohol was docked into the active site of SAHH. During the docking process, the Lamarckian genetic algorithm (LGA) was applied to the conformational search for the protein–ligand binding structure. Among a series of docking parameters, the grid size was set to be 60 Å × 60 Å × 60 Å, and the grid space was the default value of 0.375 Å. The pose with the lowest free energy of binding was selected as the best binding mode. All the molecular graphic figures were generated by PyMOL software (http://www.pymol.org).

**Results and discussion**

**Construction of recombinant vectors and screening of rsaah-positive transformants**

pPIC9K-sahh that contains a 1325 bp DNA fragment encoding a recombinant C-terminal 6 × His-tagged codon-optimized sahh was constructed in yeast (Figure 2(a)). Recombinants were verified with PCR using the primers. The size of the PCR amplified product was 1826 bp which is consistent with expected (Figure 2(b)). Pichia pastoris transformants were cultured on new yeast YPDS plates containing 0.5 mg/mL, 0.75 mg/mL, 1.0 mg/mL, 1.5 mg/mL of G418, respectively. Single colonies were picked out for PCR. Results showed that several single colonies grew well on medium with high concentration of G418, indicating that high-copy expression G418-resistant transformants were generated. Pichia pastoris has been used for the production of numerous recombinant proteins, and the strong AOX1 promoter that controls the target gene is tightly regulated and hence ideal for over expression\(^\text{15,16}\). And G418-resistant was chosen to obtain high-copy expression strains.

**Expression and purification of SAHH**

Based on the cultural condition of pH = 6.5, T = 22 °C, positive transformations were undergone the processes of fermentation, culture, induction, expression to obtain recombinant protein. After Ni-NTA affinity chromatography, the 6 × His-tagged rsaah was purified by affinity chromatography, and affinity purification was determined by 10% SDS-PAGE. The size of secreted rsaah is approximately 47.5 KDa, which is consistent with expected (Figure 3(a)). The concentration of rsaah was determined to be 914.2 mg/L. Results demonstrated that the rsaah peptide was successfully expressed.

**Determination of SAHH protein activity and parameters of enzyme kinetics**

SAH is hydrolysed by SAHH into Hcy and adenosine. And Hcy can be directly determined using Ellman reagent (DTNB)\(^\text{17}\). As shown in Figure 3(b), apparent \(K_m\) values of the hydrolytic reaction were approximately 21.8 \(\mu\)M in SAHH, whereas the \(V_{max}\) values were determined to be 22.9 \(\mu\)M/min. The enzyme kinetic parameters (\(K_m\) and \(K_{cat}\)) were calculated by least-squares fitting of the activity data at various substrate concentrations to the Michaelis–Menten equation with Origin version 8.5 software (Microcal Software, Northampton, MA). As shown in Figure 4(a,b), the optimum temperature for the SAHH enzyme was determined to be 41 °C, and optimum pH was found to be 6.5. The kinetic constants (\(K_m\), \(V_{max}\)) for the SAHH-catalyzed hydrolysis of the substrate SAH were found to fit well into a Michaelis–Menten model (double-reciprocal form of the Michaelis–Menten equation

---

**Figure 2.** (a) Schematic diagram of the P. pastoris expression plasmid, pPIC9K-sahh. The nucleotide sequence encoding 6 × His-sahh was attached in-frame. (b) rsaah-Positive transformant selected by colony-PCR, 1. 15,000 bp DNA marker. 2. pPIC9K-sahh.
Design of SAHH inhibitors and biological screening

ChemMapper is an online platform used to predict poly-pharmacology effect and mode of action for small molecules based on 3D similarity computation. ChemMapper contains >350,000 chemical structures with bioactivities and associated target annotations (as well as >3,000,000 non-annotated compounds for virtual screening)\(^1\). Picking up the user-provided chemical structure as the query, the topmost similar compounds in terms of 3D similarity are returned with associated pharmacology annotations. Neplanocin A (NepA) is a natural product known to inhibit SAHH with nanomolar activity\(^1\)\(^9\) (Table 1). However, NepA is cytotoxic upon long term exposure and shows adenosine deaminase and adenosine kinase activity. Compound 20\(^a\) (CAS:1214735-71-3)\(^19\), a novel inhibitor for SAHH, was generated by Converso. Converso reported Compound 20\(^a\) was in a position to reduce brain homocysteine in a dose-dependent manner. Inspired by Compound 20\(^a\), we obtained 338 different compounds through the ChemMapper platform (http://lilab.ecust.edu.cn/chemmapper/). Eventually, 13 compounds (Figure 5, 1–13) were singled out by the ZINC and SciFinder from the 338 selected compounds. The inhibitory effects of the thirteen small organic compounds were tested (IC\(_{50}\) are given in Table 1). We found that the SAH had a reduced hydrolysis rate with increasing inhibitor concentration and that the IC\(_{50}\) values of the tested inhibitors were comparable to those previously reported. Among them, compound 13, which is determined to be coniferyl alcohol (4-(3-hydroxyprop-1-en-1-yl)-2-methoxyphenol, CAS: 458–35-5, ZINC: 12359045), has displayed considerable inhibitory effects (IC\(_{50}\) = 34 nM). Actually, coniferyl alcohol, as a component of therapeutic agents, is being tested as a drug in treatment for breast cancer and prostate cancer\(^20\). Such results have been encouraging and suggest that coniferyl alcohol might be a valuable molecular tool for further interrogation of this promising pathway for the treatment of age-related degenerative diseases.

To test the feasibility of our design, we further performed a molecular modelling study to explore the mode of molecular interaction of coniferyl alcohol at the active site. As shown in Figure 6, coniferyl alcohol can be well docked into the active cavity of SAHH (PDB code: 1A7A). Several H-bonds obviously formed between coniferyl alcohol and the SAHH. The C1’ OH in the...
benzene ring could form an H-bond with Thr-60 and Thr-57. In addition, C2’ methoxy formed an H-bond with Hid353. These H-bonds stabilized coniferyl alcohol in the active site with a proper conformation. The predicted binding energy for ligand coniferyl alcohol was $-10.18 \text{ kcal mol}^{-1}$. Both theoretical analysis and experimental results showed that coniferyl alcohol could be well bound to SAHH and that coniferyl alcohol is likely to be selected as the inhibitor for SAHH.

SAHH, along with SAHN (S-adenosylhomocysteine nucleosidase, EC 3.2.2.9), which is involved in the recycling pathway of adenine, sulphur, and methionine in pathogens and produces a universal quorum sensing signal, autoinducer-2 (AI-2), have become attractive targets for drug design. Inhibition of SAHN would be expected to remove the quorum sensing autoinducer molecules, thus reducing the drug-resistance of pathogens$^{21,22}$. SAHH plays a critical role in the mammalian methylation process, which makes it a potential drug target in the discovery of antiviral agents and in

| Compound | SAHH IC$_{50}$ (nM) |
|----------|---------------------|
| NepA     | 1.5$^*$             |
| 20$^*$   | 40$^*$              |
| 1        | 1245                |
| 2        | 2131                |
| 3        | 913                 |
| 4        | 814                 |
| 5        | 1103                |
| 6        | 565                 |
| 7        | 1110                |
| 8        | 679                 |
| 9        | 899                 |
| 10       | 1399                |
| 11       | 986                 |
| 12       | 571                 |
| 13       | 34                  |

$^*$Data were from literature 19.

**Table 1.** Calculated IC$_{50}$ values of the most potent compounds determined for SAHH and compared with NepA and Compound 20$^*$. | Compound |
|----------|----------|
| 1        | Ade      |
| 2        | Compound 2 |
| 3        | Compound 3 |
| 4        | Compound 4 |
| 5        | Compound 5 |
| 6        | Compound 6 |
| 7        | Compound 7 |
| 8        | Compound 8 |
| 9        | Compound 9 |
| 10       | Compound 10 |
| 11       | Compound 11 |
| 12       | Compound 12 |
| 13       | Compound 13 |

**Figure 5.** Structure of thirteen SAHH inhibitors.
the treatment of age-related degenerative diseases. There is like-
wise increasing interest in determining its activity in the biological
and clinical fields with chemosensors but this has had limited suc-
cess so far. Here we report that recombinant human SAHH has
been successfully expressed in P. pastoris, and its biochemical
characteristics are analyzed in detail. Furthermore, a potential
SAHH inhibitor of coniferyl alcohol, has been singled out from 338
possible compounds, and displays efficient inhibitory effects to
human SAHH enzyme activity in vitro (IC50 = 34 nM). Additionally,
coniferyl alcohol has also shown to have better binding affinity
with human SAHH protein in computational docking studies,
which verifies its potential role for further interrogation in the
treatment of age-related degenerative diseases.

Acknowledgements

We thank Dr Weifeng Liu’s laboratory of Shandong University for
the contribution of the vector pPIC9K and P. pastoris.

Disclosure statement

The authors report no declarations of interest.

Funding

This work was supported by National Natural Science Foundation
of China (NSFC) [grant numbers 31370090, 2150704], and Project
of Key R&D of Shandong Province in China [grant numbers
2015GSF121006, BS2015SSSW023].

ORCID

Jinsong Gu http://orcid.org/0000-0003-2540-9980

References

1. Brookmeyer R, Johnson E, Ziegler-Graham K, et al. Forecasting
the global burden of Alzheimer’s disease. Alzheimers Dement
2007;3:186–91.
2. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of
dementia in the United States: the aging, demographics,
and memory study. Neuroepidemiology 2007;29:125–32.
3. Sachdev PS. Homocysteine and brain atrophy, Prog
Neuropsychopharmacol Biol Psychiatry 2005; 29:1152–61.
4. Zhuo JM, Pratico D. Severe in vivo hyper-homocysteinemia
is not associated with elevation of amyloid-beta peptides in
the Tg2576 mice. J Alzheimers Dis 2010;21:133–40.
5. Heijer T, den Vermeer SE, EJ, van Dijk, et al. Type 2 diabetes
and atrophy of medial temporal lobe structures on brain
MRI. Diabetologia 2003;46:1604–10.
6. Vugrek O, Beluzic R, Nakic N, et al. S-adenosylhomocysteine
hydrolase (AHCY) deficiency: two novel mutations with lethal
outcome. Hum Mutat 2009;30:E555–65.
7. Tehlivets O, Malanovic N, Visram M, et al. S-adenosyl-l-homo-
cysteine hydrolase and methylation disorders: yeast as a
model system. Biochimica et Biophysica Acta(BBA) - Mol
Basis Dis 2013;1832:204–15.
8. Smith DE, Smulders YM, Blom HJ, et al. Determinants of the
essential one-carbon metabolism metabolites, homocysteine,
S-adenosylmethionine, S-adenosylhomocysteine and folate,
in cerebrospinal fluid. Clin Chem Labmed 2012; 50:1641–7.
9. Snoeck R, Andrei G, Neyts J, et al. Inhibitory activity of S-
adenosylhomocysteine hydrolase inhibitors against human
cytomegalovirus replication. Antiviral Res 1993;21:197–216.
10. Liu S, Wolfe MS, Borchardt RT. Rational approaches to the
design of antiviral agents based on S-adenosyl-l-homocyste-
eine hydrolase as a molecular target. Antiviral Res 1992;19:247–65.
11. Wolfe MS, Borchardt RT. S-adenosyl-L-homocysteine hydrolase as a target for antiviral chemotherapy. J Med Chem 1991;34:1521–30.

12. Lagarde AE. DNA microarrays: a molecular cloning manual. Am J Hum Genet 2003;73:218–9.

13. Lin-Cereghino J, Wong WW, Xiong S, et al. Condensed protocol for competent cell preparation and transformation of the methylotrophic yeast Pichia pastoris. Biotechniques 2005;38:44–8.

14. Pardesi B, Tompkins GR. Colony polymerase chain reaction of heme-accumulating bacteria. Anaerobe 2015;32:49–50.

15. Zhang Y, Zhang S, Xian L, et al. Expression and purification of recombinant human neuritin from Pichia pastoris and a partial analysis of its neurobiological activity in vitro. Appl Microbiol Biotechnol 2015;99:8035–43.

16. Liu Y, Wu C, Wang J, et al. Codon optimization, expression, purification, and functional characterization of recombinant human IL-25 in Pichia pastoris. Appl Microbiol Biotechnol 2013;97:10349–58.

17. Lozada-Ramírez JD, Martínez-Martínez I, Sánchez-Ferrer A, et al. A colorimetric assay for S-adenosylhomocysteine hydrolase. J Biochem Biophys Methods 2006;67:131–40.

18. Gong J, Cai C, Liu X, et al. ChemMapper: a versatile web server for exploring pharmacology and chemical structure association based on molecular 3D similarity method. Bioinformatics 2013;29:1827–9.

19. Converso A, Hartingh T, Fraley ME, et al. Adenosine analogue inhibitors of S-adenosylhomocysteine hydrolase. Bioorg Med Chem Lett 2014;24:2737–40.

20. Park YJ, Choi C, Chung KH, et al. Pharbilignan C induces apoptosis through a mitochondria-mediated intrinsic pathway in human breast cancer cells. Bioorg Med Chem Lett 2016;26:4645–9.

21. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century – a clinical super-challenge. N Engl J Med 2009;360:439–43.

22. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerging Infect Dis 2011;17:1791–8.